Myriad: Myriad Genetics, Inc. Partners with PATHOMIQ , Inc. to Add Artificial Intelligence Technology Platform to Its Oncology Portfolio

Myriad Genetics, Inc. and PATHOMIQ, Inc. announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ's AI technology platform for prostate cancer, in the United States. Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. Adding PATHOMIQ_PRAD to Myriad's Oncology Solutions allows Myriad to provide urologist and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment. This complements Myriad's existing offerings of combined germline and comprehensive tumor profiling as recommended by NCCN guidelines for prostate cancer care. This partnership is the latest step in the strategic expansion of Myriad's oncology portfolio. The molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer. PATHOMIQ's AI-technology platform decodes hidden information from complex morphological structures across all landscapes of cancer pathology to quickly and efficiently deploy new use cases to predict patient outcome, treatment response, and genotype mutations. This image-based technology can deliver results in one to two days after receiving the digital images from the patient's sample. In addition to expanding Myriad's prostate cancer testing portfolio to include post-surgical treatment testing solutions, the collaboration with PATHOMIQ is also envisioned to accelerate the timelines for meeting Simon level 1 evidence for both Prolaris and PATHOMIQ_PRAD. While the current PATHOMIQ_PRAD model is specific for use in patients with prostate cancer after surgery, the underlying foundational model provides opportunities for applications in virtually all solid tumor cancers that are diagnosed through a biopsy with H&E staining. Myriad intends to commercially launch its first AI-driven prostate cancer clinical test later this year. About PATHOMIQ: PATHOMIQ's AI technology extracts hidden insights from complex cancer pathology to support faster and more accurate clinical decisions. By analyzing digital biopsy or surgical specimen images, it predicts patient outcomes and treatment response. This image-based approach can deliver results within one day of receiving the digital images from the patients's sample. Myriad Genetics, Inc. and PATHOMIQ, Inc. announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ's AI technology platform for prostate cancer, in the United States. Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. Adding PATHOMIQ_PRAD to Myriad's Oncology Solutions allows Myriad to provide urologist and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment. This complements Myriad's existing offerings of combined germline and comprehensive tumor profiling as recommended by NCCN guidelines for prostate cancer care. This partnership is the latest step in the strategic expansion of Myriad's oncology portfolio. The molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer. PATHOMIQ's AI-technology platform decodes hidden information from complex morphological structures across all landscapes of cancer pathology to quickly and efficiently deploy new use cases to predict patient outcome, treatment response, and genotype mutations. This image-based technology can deliver results in one to two days after receiving the digital images from the patient's sample. In addition to expanding Myriad's prostate cancer testing portfolio to include post-surgical treatment testing solutions, the collaboration with PATHOMIQ is also envisioned to accelerate the timelines for meeting Simon level 1 evidence for both Prolaris and PATHOMIQ_PRAD. While the current PATHOMIQ_PRAD model is specific for use in patients with prostate cancer after surgery, the underlying foundational model provides opportunities for applications in virtually all solid tumor cancers that are diagnosed through a biopsy with H&E staining. Myriad intends to commercially launch its first AI-driven prostate cancer clinical test later this year. About PATHOMIQ: PATHOMIQ's AI technology extracts hidden insights from complex cancer pathology to support faster and more accurate clinical decisions. By analyzing digital biopsy or surgical specimen images, it predicts patient outcomes and treatment response. This image-based approach can deliver results within one day of receiving the digital images from the patients's sample.